Navigation Links
Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
Date:7/9/2008

SEATTLE, July 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that the Medicare Improvements for Patients and Providers Act of 2008, as passed by the U.S. House of Representatives on June 24, 2008 and the U.S. Senate on July 9, 2008, would continue the 2007 reimbursement methodology for therapeutic radioimmunotherapies for an additional 18 months with a start date of July 1, 2008. In December, Congress froze reimbursement rates at the 2007 level for six months after the Centers for Medicare & Medicaid Services (CMS) had released rates for 2008 that were lower than the acquisition cost for radioimmunotherapies like Zevalin(R) (Ibritumomab Tiuxetan). Manufacturers of radioimmunotherapies and CMS have been in discussion on a payment policy that more accurately reflects hospital costs associated with the therapy. These drugs are used to fight relapsed non-Hodgkin's lymphoma (NHL), and can provide some patients with additional therapeutic options.

On July 3, 2008 CMS posted the Hospital Outpatient Prospective Payment System proposed rulemaking for Calendar Year 2009. In the rulemaking, CMS proposed to pay Zevalin and other similar products based on the Average Sales Price (ASP) methodology which is currently used for drugs and biologicals. CTI plans to submit a public comment in support of the proposal.

"We are pleased law makers have listened to the voice of patients and healthcare providers who want access to these important anti-cancer therapies," said James A. Bianco, M.D., President and CEO of CTI. "We continue to work with Congress and CMS to establish a permanent payment methodology for reimbursing radioimmunotherapies, and look forward to the President signing the bill into law."

CTI purchased the U.S. sales, marketing, and development rights to Zevalin in late 2007 from Biogen Idec, Inc. Recently CTI reached an agreement with Bayer Schering Pharma, which has rights to Zevalin outside the Unit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Axendias President to Chair 3rd Annual MES for Life Sciences Congress
2. 17th Annual Congress on Womens Health To Be Held March 27-29, 2009 in Collaboration with American Medical Womens Association (AMWA)
3. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
4. PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress
5. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
6. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
7. PTC124 Featured at Third Annual Congress of Myology
8. ULURU Inc. to Present at the 8th World Biomaterials Congress
9. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
10. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
11. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/19/2014)... 19, 2014 The Latin American hardware ... in Latin America with analysis and forecast of revenue. ... and is expected to reach $2,366.8 million by 2018, ... , Browse through the TOC of the Latin American ... the in-depth analysis provided. It also provides a glimpse ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... , , OMAHA, Neb., Dec. 8 ... of its SURVEYOR Scan K-RAS kit, the first in a ... featuring its proprietary SURVEYOR Nuclease and WAVE ® HS ... to mutation detection that uses a PCR amplification reaction and ...
... , NEW YORK, Dec. 8 Reportlinker.com ... in its catalogue: , Microplate Instrumentation & ... http://www.reportlinker.com/p0164370/Microplate-Instrumentation--Supplies---A-Global-Market-Perspective.html , Playing a pivotal role in ... has come to replace conventional micro test tubes and ...
... ... , AMSTERDAM, December 8 , ... , Elsevier, a world-leading publisher of scientific, technical ... new SciVal Spotlight tool. The institutions, including,National Chiao Tung University (Taiwan), St. ...
Cached Biology Technology:Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 2Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 3Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 4Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 5Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 6Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 7Reportlinker Adds Microplate Instrumentation & Supplies - A Global Market Perspective 8SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/16/2014)... 16, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... including Wocket™, the Smart Wallet, at the 13 th ... a leading global conference on the intersection of technology ... Mark Anderson , founder and publisher of the Strategic ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Might those bacteria lead oil companies to change their methods ... same time reducing the carbon dioxide that burning oil and ... be possible. Larter, professor of geoscience and holder ... University of Calgary, was the keynote speaker today for the ...
... a firm link between environmental change and human disease ... a team of scientists from the University of Wisconsin-Madison, ... of the CDC journal Emerging Infectious Diseases, ... incidence of malaria to land-use practices in the Amazon. ...
... bacteria in seven species of sharks and redfish captured ... of these wild, free-swimming fish harbored several drug-resistant bacterial ... Journal of Zoo and Wildlife Medicine , found antibiotic-resistant ... also found multidrug-resistant bacteria in fish at nearly all ...
Cached Biology News:Incidence of malaria jumps when Amazon forests are cut 2Incidence of malaria jumps when Amazon forests are cut 3Wild sharks, redfish harbor antibiotic-resistant bacteria 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Assay Diluent 500 mls...
ICC Diluent Buffer 250 ml...
...
Biology Products: